Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 13, Issue 11, Pages -Publisher
SPRINGER
DOI: 10.1007/s11910-013-0394-8
Keywords
Multiple sclerosis; Neuroinflammation; Oral; Immunotherapy; Neuroprotection; Clinical trial; Dimethyl fumarate; Effectiveness; Side effects
Categories
Funding
- Biogen Idec
- Merck Serono
- Novartis Pharma
Ask authors/readers for more resources
Dimethyl fumarate is an orally available treatment option for relapsing-remitting multiple sclerosis (MS) in a new formulation with improved gastroenteric coating. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects. In two pivotal phase III trials, dimethyl fumarate, 240 mg twice daily, reduced relapse rates by about 50 % as compared with placebo. In the DEFINE trial, progression of disability was also significantly reduced. Both trials demonstrated a significant reduction of gadolinium-enhanced lesions as well as T2 lesions on cranial MRI. The studies revealed a beneficial safety profile of dimethyl fumarate. The most prevalent side effects were transient flushing and gastrointestinal tract irritation. Dimethyl fumarate has recently been approved in the USA for the treatment of relapsing-remitting MS. The compound is a welcome addition to the immunomodulatory treatment armamentarium for MS patients and physicians alike.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available